Brown Advisory Inc. Sells 122,328 Shares of Avanos Medical, Inc. $AVNS

Brown Advisory Inc. lessened its stake in Avanos Medical, Inc. (NYSE:AVNS) by 6.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,808,835 shares of the company’s stock after selling 122,328 shares during the quarter. Brown Advisory Inc. owned about 3.90% of Avanos Medical worth $22,140,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its stake in shares of Avanos Medical by 969.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after acquiring an additional 2,307 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Avanos Medical during the second quarter valued at approximately $126,000. State of Wyoming increased its stake in Avanos Medical by 104.6% in the first quarter. State of Wyoming now owns 10,508 shares of the company’s stock valued at $151,000 after purchasing an additional 5,371 shares in the last quarter. EntryPoint Capital LLC bought a new stake in Avanos Medical in the first quarter valued at approximately $181,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Avanos Medical in the second quarter worth $192,000. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Stock Performance

AVNS opened at $11.27 on Friday. The company has a market capitalization of $523.11 million, a price-to-earnings ratio of -1.11 and a beta of 1.09. The business’s 50-day moving average price is $11.43 and its two-hundred day moving average price is $11.75. Avanos Medical, Inc. has a 1 year low of $9.30 and a 1 year high of $19.00. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.38 and a quick ratio of 1.36.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.10. The business had revenue of $177.80 million during the quarter, compared to the consensus estimate of $164.50 million. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.Avanos Medical’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period last year, the company earned $0.33 earnings per share. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. Equities analysts expect that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.

Insider Activity

In other news, SVP Kerr Holbrook sold 15,000 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $11.00, for a total value of $165,000.00. Following the sale, the senior vice president owned 83,860 shares of the company’s stock, valued at $922,460. The trade was a 15.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.64% of the stock is owned by company insiders.

Analyst Ratings Changes

AVNS has been the subject of several research analyst reports. Wall Street Zen raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Zacks Research lowered Avanos Medical from a “hold” rating to a “strong sell” rating in a report on Monday, December 1st. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Avanos Medical in a research note on Monday, December 1st. Two research analysts have rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.